Inspire Medical Systems (NYSE:INSP) Stock Bumped Up to “Strong Sell” by Barclays

Inspire Medical Systems (NYSE:INSP) was upgraded by equities research analysts at Barclays to a “strong sell” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

INSP has been the topic of a number of other reports. Zacks Research downgraded shares of Inspire Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 22nd. Oppenheimer raised shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a report on Tuesday, August 4th. Evercore set a $54.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Piper Sandler lifted their price objective on shares of Inspire Medical Systems from $55.00 to $60.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Finally, Stifel Nicolaus lifted their price objective on shares of Inspire Medical Systems from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, September 11th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $67.29.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $66.50 on Tuesday. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of 14.39, a P/E/G ratio of 5.10 and a beta of 0.73. Inspire Medical Systems has a 52 week low of $38.91 and a 52 week high of $147.03. The firm’s 50-day simple moving average is $64.86 and its two-hundred day simple moving average is $54.06.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. Inspire Medical Systems’s quarterly revenue was down 7.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Analysts forecast that Inspire Medical Systems will post 1.24 earnings per share for the current year.

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This represents a 4.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.20% of the company’s stock.

Hedge Funds Weigh In On Inspire Medical Systems

A number of hedge funds have recently made changes to their positions in INSP. BlackRock Inc. bought a new stake in Inspire Medical Systems in the second quarter worth about $211,341,000. ADAR1 Capital Management LLC grew its stake in shares of Inspire Medical Systems by 2,601.3% during the first quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock valued at $20,900,000 after buying an additional 390,197 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Inspire Medical Systems by 66.2% during the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after buying an additional 344,221 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Inspire Medical Systems in the second quarter worth approximately $12,021,235. Finally, Bank of America Corp DE purchased a new stake in shares of Inspire Medical Systems in the second quarter worth approximately $11,099,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.